IGM Biosciences (Nasdaq: IGMS) is a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies. IgM antibodies have inherent properties that we believe may enable them to improve upon the efficacy and safety of IgG antibodies in multiple therapeutic applications. We have created a proprietary IgM antibody technology platform that we believe is particularly well suited for developing T cell engagers, receptor cross-linking agonists, and targeted cytokines. Our lead product candidate, IGM-2323, is a bispecific T cell engaging IgM antibody targeting CD20 and CD3, and we have initiated a Phase 1 clinical trial for the treatment of relapsed/refractory B cell Non-Hodgkin's lymphoma (NHL) patients in 2019. Our second product candidate is IGM-8444, an IgM antibody targeting Death Receptor 5 (DR5) for the treatment of patients with solid and hematologic malignancies, for which we have recently initiated a Phase 1 clinical trial. Also in our product pipeline is IGM-7354, a bispecific IgM antibody delivering interleukin-15 (IL-15) cytokines to PD-L1 expressing cells for the treatment of patients with solid and hematologic malignancies.

Biotechnology

IGM Biosciences

IGM Biosciences' headquarters in Mountain View, CA, United States

Mary Beth Harler

Associate Director, Payroll

Carrie Brodmerkel

Sr. Scientist / Associate Director, Clinical Biomarkers (autoimmune Diseases)

Lisa L. Decker

Bruce Keyt

Julie Hambleton

M. Kathleen Behrens

Mark M. Davis

Michael Lee

Felix J. Baker

Jakob Haldor Topsøe

Christina Teng Topsøe

Rafi Ahmed

Gordon J. Freeman

Michael Loberg

Description

People

Jobs